Sanofi (Euronext: SAN) has signed a strategic agreement with health authorities in Abu Dhabi to accelerate vaccine ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences (Nasdaq: GILD) Yeztugo (lenacapavir) - the company’s ...

Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven ...

Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership ...

Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...

The US Food and Drug Administration has approved US biotech Incyte’s (Nasdaq: INCY) Monjuvi (tafasitamab-cxix) with ...

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

The biopharmaceutical industry is grappling with a complex mid-year outlook in 2025, as accelerating innovation collides with ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

This office will serve as Celltrion’s central hub for UK operations and places the firm among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences and Daiichi Sankyo ...

Caris Life Sciences shares ended trading at $28 per share on Wednesday, marking a 33% increase from its initial public offering (IPO) price of $21 per share.